Modern management of acute myocardial infarction is built on a clinical evidence base drawn from many studies undertaken over the past three decades. The evolution in clinical practice has substantially reduced mortality and morbidity associated with the condition. Key to this success is the eff ective integration of antithrombotic therapy combined with timely reperfusion, either primary percutaneous coronary intervention or fi brinolysis for ST-elevation myocardial infarction, and invasive investigation and revascularisation for non-ST-elevation myocardial infarction, underpinned by risk stratifi cation and optimised systems of care. After the development of troponin assays for the detection of myonecrosis, the universal defi nition and classifi cation of myocardial infarction now indicates the underlying pathophysiology. Additionally, an increasing appreciation of the importance of adverse events, such as bleeding, has emerged. Remaining challenges include the eff ective translation of this evidence to all patients with myocardial infarction, especially to those not well represented in clinical trials who remain at increased risk of adverse events, such as elderly patients and those with renal failure. On a global level, the epidemic of diabetes and obesity in the developed world and the transition from infectious diseases to cardiovascular disease in the developing world will place an increasing demand on health-care infrastructures required to deliver time-dependent and resource-intensive care. This Seminar discusses the underlying pathophysiology, evolving perspectives on diagnosis, risk stratifi cation, and the invasive and pharmacological management of myocardial infarction.
Introduction
Myocardial infarction is a major cause of morbidity and mortality worldwide. More than 3 million people each year are estimated to have an acute ST-elevation myocardial infarction (STEMI), with more than 4 million having a non-ST-elevation myocardial infarction (NSTEMI). From being an illness seen predominantly in developed countries, myocardial infarction is now becoming increasingly more common in developing countries. Commensurate with the robust evidence base on which the care of acute myocardial infarction 1,2 is now practised, registries have documented a decline in mortality. [3] [4] [5] [6] The epidemiology, basic science, and clinical evidence that inform contemporary management of acute myocardial infarction is extensive. These data span the landmark global studies that have highlighted the contribution of lifestyle factors to its incidence, explored genetic under pinnings, and provided clinical methods and biomarkers for early diagnosis and risk stratifi cation. [7] [8] [9] Many clinical trials have also explored therapeutic innovations, and there is an emerging discipline that assesses health-care systems for the optimum delivery of this care. 10 Improvements in morbidity and mortality need a comprehensive approach incorporating all evidence tailored to the specifi cs of local health-care structures (fi gure 1). This need is greater in developing countries, where progressive urbanisation has led to increasing rates of obesity, 11 diabetes, and an emerging epidemic of coronary heart disease, and where health-care services are not as well developed. 12, 13 Although several International Guidelines have reviewed this evidence in detail, 1,2,14,15 the focus in our Seminar is on management frameworks that are important for delivering the best outcomes for patients with acute myocardial infarction. commonest cause of myocardial infarction, accounting for around 70% of fatal events. 16, 17 This thrombotic process diminishes microcirculatory perfusion by reduced coronary artery fl ow through epicardial stenoses, as well as by distal embolisation of thrombus. This pathophysiology provides the rationale for fi brinolytic and antithrombotic therapies, whereas residual epicardial stenoses are targets for percutaneous and surgical revascularisation approaches. Vulnerable plaques likely to rupture or erode have evidence of infl ammation with monocytes, macrophages, and sometimes T-cell infi ltrates, together with thin fi brous caps and large lipid cores. This process involves the entire coronary vasculature, and the true culprit lesion can be diffi cult to defi ne. [18] [19] [20] Platelet hyper-reactivity and pro-coagulant states also contribute to this thrombotic disease and give rise to the idea of so-called vulnerable blood. 21, 22 Additionally, coronary spasm, emboli, or dissection of the coronary artery are causes of infarction in the absence of occlusive atherosclerosis, and are reported in 5-10% of patients with STEMI and 10-15% of patients with NSTEMI. 18 Similar proportions of patients with non-ST-elevation acute coronary syndromes (NSTEACS) have angio graphically normal coronary arteries despite elevated troponins 23 and myocardial infarctions detected by MRI. 24 Epidemiological studies have underscored the contribution of lifestyle factors in the development of atherosclerosis and myocardial infarction. In the INTERHEART study 25 of over 15 000 patients, 90% of myocardial infarctions were attributable to modifi able risk factors such as smoking, dyslipidaemia, hypertension, abdominal obesity, and diabetes in men (94% in women). Novel imaging techniques such as MRI and CT scanning might have a future role in refi ning risk assessment, especially in identifying patients at low risk in whom preventive therapies might not be justifi ed. Similarly, a greater understanding of the genetic foundation could off er more accurate identifi cation of patients at heightened risk, where more aggressive prevention strategies might be warranted. 26 Although several genetic variants delineating important disease pathways have been defi ned, their translation to eff ective preventive strategies needs further study.
New defi nitions
In 2000, the European Society of Cardiology and the American College of Cardiology Consensus group redefi ned myocardial infarction, with the defi nition being based on myocyte necrosis as determined by troponins in the clinical setting of ischaemia. Troponin T and I, more sensitive and specifi c measures of myocyte necrosis than creatine kinase or creatine kinase-MB (panel 1), 27 have been associated with a 60-80% increase in incidence of myocardial infarction in patients presenting with suspected acute coronary syndrome (fi gure 2). Challenges with implementation of the new defi nition have included the availability of troponin assays with suffi cient diagnostic precision and the interpretation of raised troponin levels in the context of other plausible diff erential diagnoses. 27 In this regard, although coronary ischaemia is the most common cause of troponin elevation, it is one of many causes, and the interpretation of an elevated troponin should be assessed within the entire clinical context (panel 2). All causes of elevated troponin indicate a worse prognosis than if troponin levels are not elevated, and in the absence of a clinical presentation suggestive of coronary ischaemia, a search for other causes is needed. A universal defi nition developed by an international task force 28 includes a clinical classifi cation with fi ve diff erent types of myocardial infarction (panel 1). This classifi cation incorporates the underlying pathophysiology, with implications for diff ering treatment approaches-eg, the treatment of anaemia or hypotension in type II myocardial infarction, as opposed to antithrombotic therapy and reperfusion or re vascularisation in type I. Clinical coding will need to follow this classifi cation and clinical trials should report the diff erent types of myocardial infarction in a standard manner so as to assess the eff ects of various therapies.
The range of normal ST-segment deviation diff ers between men and women. ST-elevation in the V 2 or V 3 leads of 2·0 mV or less in men and 1·5 mV or less in women, or 1·0 mV or less in other leads, is normal. 28 ST-elevation exceeding these levels should be used for assessing reperfusion eligibility in the appropriate clinical context.
Beyond these defi nitions is the important idea of aborted myocardial infarction, where early reperfusion therapies can prevent detectable myonecrosis. Aborted myocardial infarction is seen in up to 25% of patients treated within 1 h of symptom onset with fi brinolysis, depending on the sensitivity of measures used.
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Risk stratifi cation
The rapid and accurate assessment of risk is important for eff ective management of patients. The appropriate allocation of time-critical resources-such as systems of transport, invasive management, and the coordinated use of pharmacotherapies-requires accurate risk assessment to optimise patient outcomes and mitigate adverse events and costs. Although several risk scores in patients with STEMI and NSTEMI have been developed, their use lies not only in improved appreciation of risk and communication to patients, but also in identifying patient subsets who warrant a diff erent treatment approach. 8, 9, [30] [31] [32] The best risk score for prediction of death and myocardial infarction seems to be the Global Registry for Acute Coronary Events (GRACE) score that incorporates renal dysfunction (tables 1 and 2). 33 The incorporation of other risk parameters such as biomarkers (eg, B-type natriuretic peptide), extent of disease on imaging, genetic markers, as well as functional and socioeconomic factors into the current risk models, and their ability to guide the use of current and novel therapies needs prospective assessment. 26, 34, 35 
Management
Management involves a complex interplay between rapid restoration of epicardial and microvascular blood fl ow by pharmacological and catheter-based means, suppression of recurrent ischaemic events through optimised antithrombotic therapies, and treatments aimed at mitigating the eff ect of myocardial necrosis and preventing future events. Key ideas and treatment frameworks necessary for aff ecting improved clinical outcomes are shown in fi gure 3.
Reperfusion for STEMI Fibrinolysis
Emergent pharmacological reperfusion with fi brinolysis remains the principal treatment for improving survival after STEMI. 36 Development of fi brinolytics has changed from non-fi brin specifi c agents (streptokinase and urokinase) by intravenous infusions, to infusions of fi brin-specifi c agents (tissue plasminogen activator [tPA]) 37 with a mortality ad vantage over streptokinase, to bolus-only fi brin-specifi c agents (rPA, 38 TNK-tPA 39 ), which achieve greater vessel patency than streptokinase and similar mortality benefi t as tPA, less systemic bleeding than tPA (TNK-tPA), 39 and have the advantage The earlier that fi brinolysis is begun, the greater the benefi t with respect to preservation of left-ventricular function and reduction in mortality, which suggests an important role for prehospital fi brinolysis. [40] [41] [42] In a study of prehospital fi brinolysis with a 26% rate of rescue percutaneous coronary intervention (PCI), fewer patients randomised within 2 h of symptom onset had cardiogenic shock (1·3% vs 5·3%, p=0·03) and more survived to 30-days (2·2% vs 5·7%) when compared with primary angioplasty, although this fi nding was not signifi cant (p=0·058). 41 Although studies confi rming these observations are needed, the development of clinical networks designed to enable prehospital fi brinolysis could provide further mortality benefi ts to a broader population of patients presenting with STEMI.
Catheter-based reperfusion
Although primary PCI is resource-intensive and more diffi cult to quickly implement than fi brinolysis, when both options are available, primary PCI seems to off er better clinical outcomes. A meta-analysis of 23 randomised trials with 7739 patients showed that primary PCI resulted in a lower rate of early death (7% vs 9%, p=0·0002), non-fatal reinfarction (3% vs 7%, p<0·0001), and stroke (1% vs 2%; p=0·0004) than fi brinolysis. 43 The benefi t of PCI over fi brinolysis is evident when patients are treated early after symptom onset and increases with greater delay in presentation. 44 The advent of percutaneously placed emboli protection devices and drug-eluting stents have not provided further reductions in acute (30-day) mortality. 45, 46 The benefi t of PCI over fi brinolysis remains dependent on timely implementation, with some analyses suggesting that the incremental benefi t is lost with a relative delay (door-to-balloon time 47 vs door-to-needle time [PCI]) of between 60 min and 114 min, with less tolerance in high-risk patients. 48, 49 There is a complex interplay between patient age, infarct location, and initial delay in presentation, and the tolerable delay for achieving the benefi t of primary PCI over fi brinolysis. In general, the improved outcome of primary PCI over fi brinolysis is lost earlier in patients younger than 65 years of age and in those presenting within 120 min of symptom onset (fi gure 4). Therefore, the advantage of primary PCI over fi brinolysis is dependent on effi cient and eff ective clinical systems that are able to deliver timely and consistent reperfusion.
The key logistical challenge of a primary PCI strategy is the extension of this approach to hospitals without invasive services. Of 4278 patients transferred from other centres for primary PCI drawn from the National Registry of Myocardial Infarction 3 and 4 database in the USA, the median door-to-balloon time was 180 min, with only 4·9% of patients treated within the 90 min recommended in clinical guidelines. 50 The potential value of established health-care networks has been examined in several studies with promising results. [51] [52] [53] In the DANAMI-2 study, 52 transfer for PCI was associated with lower rates of stroke, recurrent myocardial infarction, and unplanned revascularisation than was onsite fi brinolysis, but there was no reduction in mortality. The value of such networks needs careful local assessment. 48 
Failed reperfusion
Failure to achieve microvascular fl ow, as assessed by resolution of ST-segment elevation or contrast fl ow by angiography, is seen with fi brinolysis (in up to around 40% of patients) and primary PCI (in around 25%). 54, 55 Factors associated with failed reperfusion include delay to presentation, infarct location, and concomitant therapies. 56 These suboptimum outcomes have led to pharmacological strategies aimed at improving the effi cacy of reperfusion with adjunctive pharmacology before and combined with invasive strategies.
Invasive management after pharmacological reperfusion
In view of the logistical constraints of providing primary PCI to all patients presenting with STEMI, several hybrid pharmacoinvasive strategies have evolved, seeking to take advantage of the ease of fi brinolysis combined with the treatment of the culprit lesion with PCI. 57 
Rescue PCI
In patients who receive fi brinolysis, accumulating evidence supports the role of emergent angiography and rescue PCI for failed reperfusion, defi ned as ongoing chest-pain, failure of ST-segment resolution by more than 50% at 90 min after fi brinolysis, or both. In a meta-analysis of eight trials with 1117 patients, rescue PCI was associated with lower rates of death, heart failure, and reinfarction by 6 months (29·2% vs 41·0%, 11·8% absolute reduction, 95% CI 5-18, p<0·001) than was a conservative strategy with PCI only for recurrent ischaemia after fi brinolysis. A non-signifi cant reduction in mortality (odds ratio [OR] 0·69, 95% CI 0·23-1·05, p=0·09) was observed but rescue PCI was associated with a 3% (95% CI 0-5, p=0·02) absolute increase in the risk of stroke. 47 PCI for reinfarction after fi brinolysis is also better than readministration of fi brinolysis. 58 
Facilitated PCI
Routine emergent PCI after fi brinolysis (ie, very early PCI without ongoing evidence of failed reperfusion) or facilitated PCI has not been associated with benefi ts. The ASSENT-4 PCI (Assessment of the Safety and Effi cacy of a New Treatment Strategy with Percutaneous Coronary Intervention) study 59 of 1667 patients reported an increase in the composite of death, heart failure, and shock compared with primary PCI alone (18·6% vs 13·4%, p=0·005). Meta-analysis including the ASSENT-4 PCI study reached the same conclusions. 60 Also the Facilitated Intervention for Enhanced Reperfusion Speed to Stop Events (FINESSE) trial showed no benefi t of facilitated PCI following half-dose r-PA and abciximab (a potentially more robust antithrombotic approach) compared with primary PCI in 2653 patients. 61 Whether a facilitated PCI strategy has a role in clinical settings where primary PCI is associated with substantial delays (6-12 h) needs more study. 57 
Routine PCI after fi brinolysis
Early PCI within 24 h could consolidate the benefi ts of successful reperfusion. 62 Meta-analyses of three trials which compared routine PCI with stenting after fi brinolysis to ischaemia-guided stenting after fi brinolysis showed a reduction in death of 3·8% vs 6·7%, OR 0·56; 95% CI 0·29-1·05), p=0.07 and a signifi cant reduction in death and myocardial infarction at 6 months 7·4% vs 13·2%, p<0·01. 63 Small studies have also suggested benefi ts with PCI 3-12 h after fi brinolysis in the context of more robust antithrombotic therapies for improved epicardial fl ow and tissue perfusion. 61, 64 In a small study, early fi brinolysis and PCI within 24 h achieved similar outcomes to primary PCI. 65 A pharmacoinvasive strategy of immediate fi brinolysis and early revascularisation would be practicable in many parts of the developed world, but these results need to be considered carefully in the context of the negative fi ndings associated with facilitated PCI. Collectively, these data seem supportive of very early invasive management after fi brinolysis with reduced composite outcomes of death, recurrent myocardial infarction, and recurrent ischaemia, although these gains are more evident in recurrent myocardial infarction or ischaemia and in patients with ongoing ischaemia (rescue PCI). However, although these questions are the focus of clinical research worldwide, with emerging promising results, fi rm recommendations regarding early invasive management (2-6 h after fi brinolysis) in patients without ongoing ischaemia cannot be made.
Management of occluded infarct-related arteries
The open artery theory 66, 67 postulated that late infarct artery patency would improve left-ventricular remodelling, 68 decrease arrhythmias, and reduce future events through provision of collaterals. This theory was tested in the Occluded Artery Trial, 69 where 2166 patients with an occluded artery within 3-28 days after myocardial infarction were randomised to either PCI or optimum medical management. There was no benefi t of PCI for the composite of death, myocardial infarction, or heart failure (17·2% PCI and 15·6% medical therapy [hazard ratio 1·16; 95% CI 0·92-1·45, p=0·20]). Medical management is the recommended treatment for patients with occluded infarct-related arteries 24 h after symptom onset who are free of ongoing ischaemia.
Invasive management of NSTEACS
The rationale for treating the culprit lesion with PCI has been extended to patients without STEMI. Several studies have explored the role of routine invasive management versus a conservative ischaemia-driven strategy in NSTEACS. [70] [71] [72] [73] [74] [75] These data have been analysed in two meta-analyses. 76, 77 The fi rst included seven trials (n=9212) and recorded a greater rate of in-hospital death or myocardial infarction with an invasive strategy (conservative 3·8% vs invasive 5·2%; OR 1·36; 95% CI 1·12-1·66, p=0·002) but a lower rate of these events after hospital discharge (conservative 11·0% vs invasive 7·4%; OR 0·64; 95% CI 0·56-0·75, p<0·001) than with conservative therapy. A greater benefi t was seen with troponin elevation. 76 The lack of consistent benefi t should be noted and is probably attributable to trial diff erences in the timing of the invasive approach, the proportion of patients undergoing invasive management in the invasive groups (44%-82%) 70, 74 and conservative groups (9%-40%), 71, 75 and the antithrombotic therapies used. A sub sequent meta-analysis of more contemporary studies with higher rates of glycoprotein IIb/IIIa inhibition, and use of clopidogrel, noted a 17% relative reduction in late mortality (OR 0·83, 95% CI 0·72-0·96, p=0·012) with the routine invasive strategy compared with an ischaemia-driven approach. 77 In the 5 year follow-up of RITA-3, 77 rates of death or myocardial infarction were reduced from 20·0% to 16·6% (OR 0·61; 95% CI 0·61-0·99, p=0·044) and there was a non-signifi cant reduction in death from 15·1% to 12·1% (OR 0·76, 95% CI 0·81-1·00, p=0·054), further supporting the routine early invasive strategy Clinical evidence suggests that early provision of an invasive strategy (within 48-72 h of presentation) is important in achieving this benefi t. [78] [79] [80] In a comparison of 410 patients with acute coronary syndrome receiving aspirin, clopidogrel, tirofi ban, and heparin randomised to invasive therapy within 6 h of presentation or after a cooling off period of 3-5 days, a benefi t with very early invasive management was seen. 79 Although small, this study reported a lower rate of 30-day death or myocardial infarction (5·9% vs 11·9%, p=0·04) in patients treated within 6 h, with all the diff erence accounted for by myocardial infarctions occurring before invasive therapy in the delayed group. 78 Hence, where clinically appropriate, after considering comorbid conditions, early invasive management should be implemented as early as possible.
Acute phase adjunctive pharmacotherapies
Modern management of myocardial infarction has evolved to an increased use of invasive management, but this transition has only been enabled by developments in antithrombotic therapies. Improved appreciation of the role of platelet activation and aggregation in ongoing ischaemic events has led to the use of more eff ective antiplatelet therapies. Likewise, alternative approaches to antithrombin therapies beyond unfractionated heparin have been developed. The clinical challenge is the optimum combination of these therapies for eff ective suppression of ischaemic events, while avoiding bleeding events, in the context of invasive management that often includes coronary artery bypass grafting.
Antiplatelet therapies
Since the early fi brinolytic studies, 81 aspirin 150-325 mg has been a mainstay treatment for all patients undergoing either pharmacological or catheter-based reperfusion, and recommendations have been made that all patients with acute coronary syndromes and without contra indications should receive aspirin 150-300 mg. 82, 83 Clopidogrel, a thienopyridine antagonist of ADP, is recommended for acute coronary syndromes in the absence of contraindications. Patients younger than 75 years treated with fi brinolysis randomised to receive clopidogrel (300 mg loading dose and 75 mg daily compared with placebo) achieved improved rates of vessel patency 3-5 days later with a non-signifi cant reduction in myocardial infarction (2·5% vs 3·6%: p=0·08). 84 These results are, however, supported by a 7% reduction in hospital mortality with clopidogrel (75 mg a day added to aspirin, without a loading dose) among 45 852 patients with myocardial infarction, irrespective of reperfusion status (7·5% vs 8·1%, p=0·03). 85 In a randomised study 86 of 12 562 NSTEACS patients, comparing clopidogrel 300 mg loading and 75 mg daily to placebo on a background of aspirin, a 20% relative risk reduction in cardiovascular death, non-fatal myocardial infarction, and stroke was observed (clopidogrel 9·3% vs placebo 11·4%; relative risk [RR] 0·80, 95% CI 0·72-0·90, p<0·001). A higher loading dose of clopidogrel (600 mg) has been shown to achieve more rapid platelet inhibition 87 and is being tested in trials. There is an increased bleeding risk with coronary artery bypass grafting within 5 days of taking clopidogrel and early initiation needs to be carefully considered in patients where clinical feature could suggest the need for early surgical revascularisation. 88 Prasugrel irreversibly inhibits the P2Y 12 receptor at the same site as clopidogrel, and has been shown to be better than clopidogrel in patients with NSTEACS particularly in those with diabetes for reducing a composite of cardiovascular death, myocardial infarction, stroke, and to reduce late stent thrombosis, but to increase major bleeding. 89 
Glycoprotein IIb/IIIa antagonists
In patients undergoing primary PCI, abciximab, a chimeric monoclonal antibody fragment targeting the glycoprotein IIb/IIIa receptor, is associated with a reduction in the composite ischaemic endpoints of death, recurrent myocardial infarction, and urgent revascularisation. [90] [91] [92] One meta-analysis also reported a reduction in mortality. 92 Small molecule glycoprotein IIb/IIIa inhibitors (tirofi ban and eptifi batide) have not been extensively studied, 92 although mechanistic studies have suggested improved vessel patency. 93, 94 Trials of half-dose fi brinolytics and glycoprotein IIb/IIIa inhibition for pharmacological reperfusion have also indicated improved patency and more rapid ST-segment resolution, and less recurrent infarction than with standard fi brinolytic therapy, but no reduction in mortality. 38 In a meta-analysis of 31 402 patients with NSTEACS, glycoprotein IIb/IIIa antagonists initiated early after admission reduced death and myocardial infarction by 9% at 30 days (p=0·015). Major bleeding occurred in 2·4% of patients receiving IIb/IIIa antagonists vs 1·4% of patients receiving placebo (p<0·0001). 95 The treatment eff ect was larger (18% reduction in death and myocardial infarction) in patients who had elevated troponin levels (9·3% vs 11·3%, p<0·001).
Antithrombotic therapies
Despite limited data supporting its use, unfractionated heparin remains the most common antithrombotic therapy used for the management of myocardial infarction. In patients receiving fi brin-specifi c fi brinolytic agents, unfractionated heparin commenced early after fi brinolysis is recommended, although the independent benefi t of such treatment has not been fully defi ned. The use of adjunctive unfractionated heparin with streptokinase has been controversial, although a meta-analysis has shown a reduction in mortality compared with placebo. 96 In a meta-analysis of six randomised studies of patients with NSTEACS, unfractionated heparin added to aspirin was associated with a non-signifi cant reduction in death or myocardial infarction (OR 0·67, 95% CI 0·44-1·02; p=0.06). 97 Limitations of unfractionated heparin include a variable therapeutic response depending on age, weight, and renal function, and the requirement for monitoring of activated partial thromboplastin time. Low molecular weight heparins have anti-Xa and anti-IIa activity, high bioavailability, provide more consistent anticoagulation avoiding the need for monitoring, and are associated with a lower risk for heparin-induced thrombocytopenia than unfractionated heparin. Most of the current data are with enoxaparin, 98 with some earlier studies assessing dalteparin in NSTEACS. 99 In 20 479 patients with STEMI receiving fi brinolysis, enoxaparin administered for 4-7 days compared with unfractionated heparin for 48 h reduced the risk of death and non-fatal myocardial infarction at 30 days (9·9% vs 12%, RR 0·83, p<0·001), with an increase in major bleeding (2·1% vs 1·4%, RR 1·53, p<0·001). 100 Enoxaparin is a suitable antithrombotic with fi brin and non-fi brin specifi c fi brinolytics. Dose adjustment is necessary in patients over 75 years of age and patients with renal failure. 101 In NSTEACS, a meta-analysis of trials comparing enoxaparin to unfractionated heparin reported an overall 9% reduction in death and myocardial infarction at 30 days, with a greater eff ect of 20% seen in trials using more conservative management and when time to PCI was greater. 102 In studies where most patients had early angiography, an increase in major bleeding was also evident in patients receiving enoxaparin compared with unfractionated heparin, with similar rates of death or myocardial infarction at 30 days and 6 months. 103 Enoxaparin is recommended with conservative management and as an alternative to unfractionated heparin with an early invasive strategy.
Direct thrombin inhibitors
In patients with STEMI, bivalirudin, a short-acting direct thrombin inhibitor used as an adjunct to streptokinase, was not associated with any further reduction in 30-day mortality. 104 In primary PCI, bivalirudin reduced major bleeding from 8·3% to 4·9% (p<0·001), compared with unfractionated heparin with a IIb/IIIa antagonist. 30-day cardiac mortality and total mortality were reduced (2·1% vs 3·1%, p=0·047), suggesting this agent might be the antithrombotic agent of choice in primary PCI. 105 For moderate-risk and high-risk NSTEACS and unstable angina, bivalirudin had similar ischaemic benefi t as either unfractionated heparin or enoxaparin with a IIb/IIIa antagonist but a 47% reduction in major bleeding (3·0% vs 5·6% p<0·001) 106, 107 and is an appropriate choice for these patients.
Factor X inhibition
Fondaparinux, a synthetic factor Xa inhibitor, has been found to reduce 30-day death or myocardial infarction in patients receiving fi brinolysis (10·9% vs 13·6%; p<0·05) and in those not receiving fi brinolysis (12·2% vs 15·1%; p<0·01) compared with unfractionated heparin or placebo. 108 In patients undergoing primary PCI there was no benefi t with fondaparinux, with an excess of catheter thrombosis noted.
In 20 078 patients with NSTEACS, fondaparinux was similar to enoxaparin at 9 days for the composite endpoint of death, myocardial infarction, or refractory ischaemia (5·8% fondaparinux vs 5·7% enoxaparin), but a 48% reduction in major bleeding (4·1% to 2·2%) was reported (p<0·0001). 109 A reduction in mortality with *Fondaparinux and bivalirudin can be used without dose adjustment above a creatinine clearance of 30 mL/min. Enoxaparin should be dose adjusted to 1 mg/kg subcutaneously once a day for creatinine clearance <60 mL/min and not used in patients with creatinine clearance <30 mL/min. †Heparin induced thrombocytopenia is the most common form. fondaparinux was seen at 6 months (5·8% vs 6·5%, p=0·05). Catheter-related thrombus was again seen in patients undergoing PCI, although this fi nding was mitigated by the addition of unfractionated heparin.
Fondaparinux is an appropriate choice in patients with STEMI treated and not treated with fi brinolysis and in patients with NSTEACS, but should not be used with primary PCI.
Combination of antithrombotic therapies
Integration of antithrombotic therapies into a single strategy that optimises ischaemic outcomes, while reducing bleeding risk, remains challenging, particularly in patients at increased risk of bleeding undergoing invasive management. Consideration also needs to be given to the timing of angiography and possible PCI. In general, all patients should receive aspirin and clopidogrel and one antithrombin agent (unfractionated heparin, enoxaparin, bivalirudin, or fondaparinux, but not a combination). Where there is an increased bleeding risk and an invasive strategy is planned, use of bivalirudin is supported by strong data, 106, 107 whereas for patients in whom conservative management is planned, fonda parinux is associated with reduced bleeding and mortality. 108, 109 Recommended choices of antithrombotic agent according to indications, timing of intervention, bleeding risk, renal failure, and presence of thrombocytopenia are given in table 3.
Evidence supports the additive benefi ts of combination antiplatelet agents (aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibition). For patients with elevated troponin levels undergoing PCI, abciximab in addition to clopidogrel and aspirin further reduces ischaemic events. 110 Glycoprotein IIb/IIIa inhibition commenced in the catheterisation laboratory rather than soon after admission has been shown to reduce major bleeding (4·9% vs 6·1%, p<0·01) with a non-signifi cant increase in ischaemic events (7·9% vs 7·1%, p=0·13), although the 95% confi dence limits do not exclude a 29% increase. 111 Thus aspirin, clopidogrel, and an antithrombin agent should be commenced soon after admission, whereas initiation of a glycoprotein IIb/IIla inhibitor can be deferred until assessment with angiography. Ongoing trials will refi ne this approach.
Complications of myocardial infarction
Mortality from myocardial infarction has been decreasing. Data from GRACE for 1999 and 2006 3 reported a 3·9% (95% CI 1·9-5·3, p<0·001) absolute risk reduction in hospital deaths for patients presenting with STEMI and 0·7% (95% CI -0·3 to 1·7, p=0·02) for those presenting with NSTEACS, with a 2·7% (95% CI 0·5-4·3, p=0·02) absolute reduction in cardiogenic shock and heart failure. Most deaths in hospitalised patients with STEMI or NSTEMI are due to heart failure and mechanical complications including: myocardial rupture; mitral regurgitation due to papillary muscle dysfunction or chordal rupture; and ventricular septal rupture. Despite contemporary therapies including reperfusion, emergent revascularisation, and intra-aortic balloon pumping, half of patients with cardiogenic shock will die. 112 Compared with the pre-reperfusion era, fatal ventricular tachyarrhythmias are now less common, although sudden cardiac death remains a substantial cause of late mortality in those with severe impairment of left ventricular function (ejection fraction <35%).
Bleeding
The importance of iatrogenic bleeding and the relation with mortality is increasingly recognised. These events are the result of an interaction between potent antithrombotic therapy, invasive management, and an increasing prevalence of factors that predispose to bleeding including advanced age, hypertension, and renal impairment. [113] [114] [115] Why bleeding is associated with a roughly 5-fold increased late mortality is not known, but possibilities include hypotension resulting in myocardial ischaemia and infarction, trans fusion-associated diseases, and cessation of therapies such as aspirin and clopidogrel with loss of their benefi ts.
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Therapeutic approaches to reducing secondary events
Adherence to proven therapies and control of lifestyle factors such as smoking, obesity, lack of exercise, and cardiac rehabilitation are important for improving outcomes. Systematic analysis of 63 randomised secondary prevention studies (21 295 patients) has clearly indicated sustained mortality benefi ts (risk ratio 0·85, 95% CI 0·77-0·94) associated with these programmes, irrespective of the inclusion of structured exercise components. However, the cost-eff ectiveness implications require further clarifi cation. 116 Beyond the initial phase of management, both aspirin and clopidogrel have been associated with further reductions in ischaemic events and should be continued indefi nitely for aspirin and for 3-12 months for clopidogrel. Angiotensin-converting enzyme (ACE) inhibitors are indicated in patients with heart failure, anterior infarction, or a history of previous infarction. These agents exert some of their eff ects on reducing left ventricular remodelling (fi gure 5). 117, 118 Angiotensin II receptor blockers have a role when ACE-inhibitors are not tolerated. 119 In the absence of severe renal dysfunction or hyperkalaemia, post-myocardial infarction patients with an ejection fraction of less than 40% or heart failure should receive an aldosterone anta gonist. 120 Much evidence supports the use of statin therapy as secondary prevention after acute coronary syndromes, with these agents providing substantial reductions in mortality as well as in non-fatal ischaemic events. 121 Although data suggest that early initiation of statin therapy might provide further reductions in ischaemic events, a meta-analysis of 12 clinical trials with 13 024 patients enrolled soon after an acute coronary event found no signifi cant reduction in death, recurrent myocardial infarction, and stroke at 30 days compared with placebo, low-dose statins, or usual care. 122 In another study, metoprolol was associated with no reduction in mortality but with fewer recurrent myocardial infarctions (metoprolol 2·0% vs placebo 2·5%; OR 0·82; 0·72-0·92; p=0·001) and episodes of ventricular fi brillation (2·5% vs 3·0%; OR 0·83; 0·75-0·93; p=0·001), irrespective of reperfusion status. This benefi t was associated with an increase in the risk of cardiogenic shock (5·0% vs 3·9%; OR 1·30; 1·19-1·41, p<0·0001). 123 Although the relative benefi t of β blockers after myocardial infarction in the context of more aggressive revascularisation is unclear, these agents are recommended. Long-acting agents (carvedilol, bisoprolol, and metoprolol succinate) should be given to those patients with substantial reductions in left ventricular function.
Implantable defi brillators
Robust evidence supports the use of implantable cardioverter-defi brillators in patients with life-threatening ventricular arrhythmias with (and without) an ischaemic basis, especially in the presence of reduced left-ventricular function. This evidence extends to the primary prevention of sudden cardiac death. [124] [125] [126] Cardioverter-defi brillators are better than conventional antiarrhythmic therapies in patients with a left-ventricular ejection fraction of 35% or less and inducible ventricular tachycardia on electrophysiologic testing (hazard ratio 0·46; 95% CI 0·26-0·92, p<0·009). They are also preferable after myocardial infarction (>30 days after the event) in patients with left ventricular ejection fraction of 30% or less without any electrophysiological risk criteria (hazard ratio 0·69; 95% CI 0·51-0·93; p=0·02). 125, 126 A challenge is the generalisability of these data, including their application to elderly patients and those with signifi cant comorbidities.
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Special patient groups
Specifi c patient subgroups, namely elderly people, 128, 129 people with diabetes, 130, 131 and those with renal dysfunction, [132] [133] [134] endure a disproportionate burden of the morbidity and mortality associated with myocardial infarction. However, proven therapies such as fi brinolysis and early revascularisation remain under-used, despite evidence suggesting a greater absolute benefi t. [135] [136] [137] [138] For example, in NSTEACS patients with diabetes at presentation, a 1·78-fold (95% CI 1·24-2·56, p<0·001) increase in mortality is evident at 30 days and a 1·65-fold (95% CI 1·30-2·10, p<0·001) increase is evident at 1 year. 130 Similarly, the absolute benefi t of a routine invasive approach in terms of death or myocardial infarction at 6 months in NSTEACS was greater in patients older than 65 years than in those aged 65 years and younger within an observational analysis of the TACTICS-TIMI-18 study (invasive 10·8% vs conservative 21·6%; p=0·016), although an increased risk of bleeding was also seen in elderly patients. 138 Many current recommendations rely on subgroup analyses of larger trials, with limited capacity to detect moderate treatment diff erences among these high-risk groups. To improve the evidence base on which specifi c recommendations can be made, future clinical trials validating current therapies and exploring new approaches or specifi c treatment strategies to ameliorate excess risk are required. Dose attenuation by age has been formally studied with enoxaparin in patients receiving fi brinolysis, with reduced bleeding events observed.
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Novel therapies
Results of studies of several novel therapies, including complement inhibitors, 139 glucose-insulin potassium, 140 and peri-infarction cooling, have been disappointing. 141 Pexelizumab, a C5 complement inhibitor was studied Figure 6 : Missed opportunities in reperfusion for STEMI Estimates of the proportion of all STEMI patients receiving either fi brinolysis or catheter-based reperfusion (italic) at various degrees of delay, combined with literature-based estimates of mortality observed with the reperfusion modality and associated delay (parentheses). Excess deaths estimated by multiplying the excess mortality rate above primary PCI undertaken within 2 h of onset of symptoms by the proportion of patients at risk in a cohort of 10 000 patients presenting with STEMI. 44, 135 as an adjunctive agent with primary PCI. 139 There was no eff ect on mortality by 30 days (4·1% vs 3·9%, p=0·78). Of 20 201 patients treated with fi brinolytic therapy, infusions of glucose-insulin-potassium irrespective of diabetic status have also shown no additional benefi t over standard therapy. 140 Nevertheless, control of acute hyperglycaemia in those with raised glucose levels, and ongoing management of glucose control for patients with newly diagnosed and established diabetes, is strongly recommended. Hypothermia to a temperature of 33°C to decrease myocardial metabolism showed no overall reduction in infarction size, although there was a small reduction for patients with anterior myocardial infarctions. 141 Whether reparative approaches such as stem cell therapies are able to provide substantial improvements in cardiac morbidity and sudden cardiac death among patients with severe left-ventricular impairment is still being researched.
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The last mile Despite this rich evidence base, large-scale registries have documented missed opportunities in the provision of reperfusion therapy and other proven therapies. [135] [136] [137] 143 Clinical outcome studies show the strong association between the lack of provision of care and non-adherence, with increased late mortality in patients presenting with acute coronary syndromes. [144] [145] [146] Evidence from GRACE indicates that almost 40% of STEMI patients receive no reperfusion therapy. 135 Improving the proportion of patients receiving reperfusion and decreasing the delay in delivering reperfusion would save more lives than changing from the strategy of fi brinolysis to primary PCI or introducing novel adjunctive therapies to current reperfusion practices (fi gure 6). Increasing the numbers of patients treated with reperfusion therapy would save an estimated 270 lives per 10 000 STEMI patients. Reducing time to lysis or changing to a PCI strategy from lysis would save an estimated 154 lives per 10 000 STEMI patients. The eff ect of a novel therapy reducing mortality by 20% to patients receiving optimal reperfusion (PCI less than 2 h) would result in one life saved per 10 000 patients with STEMI. Hence, these studies suggest the potential for greater improvements in patient outcome with improved care delivery compared with the potential gains from therapeutic innovations, especially among understudied and underserved groups where adverse outcomes remain high.
Several initiatives have explored the engineering of better health-care systems aimed at improved provision of timely and eff ective care for patients. 53, 147, 148 Such programmes have sought to imbed methods aimed at increasing application of proven therapies, used clinical networks with common protocols, and promoted a culture of objective assessment of clinical care.
Importantly, substantial 1-year mortality reductions have been reported with such initiatives (OR 0·53; 95% CI 0·36-0·76, p=0·0006). 148 Similarly, focused analysis of the care processes can inform the design of better local clinical systems. 149 Further studies focusing on the determinants of poor adherence, lack of evidence application, systems of care, and their association with patient outcomes are required. The resources required to optimally implement these system changes are unclear, and formal cost-eff ectiveness evaluation of such initiatives could help priori tise future resource allocation to research and health care.
Conclusion
Therapeutic options for treatment of patients with myocardial infarction have improved substantially over the past 25 years. Our understanding of the pathophysiology has also meant a shift in our focus. Biotechnological innovation, such as gene modulating strategies to favourably aff ect infl ammation, remodelling, oxidated stress, and angiogenesis are being tested in animal studies and might further change the current framework of optimum treatment for patients. However, the largest gains are likely to come from improvements in the eff ectiveness of our ability to apply these therapies.
In view of the predicted increase and distribution of myocardial infarction mortality in the next 20 years, a crucial task in the global health agenda is to ensure that clinical and system-specifi c lessons learned from the research largely done in the developed world are eff ectively translated to the emerging epidemic in the developing world. 
